LabGenius raises $10M to use AI for protein drug discovery
LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding.
The round is led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Air Street Capital and existing investors. Also investing is Recursion Pharmaceuticals’ founder and CEO Chris Gibson, as well as Inovia Capital General Partner Patrick Pichette, who was formerly Google’s CFO.
Lux Capital’s Zavain Dar and Obvious Ventures’ Nan Li will join the LabGenius board of directors. Notably, the U.K. company’s early investors include Nathan Benaich, Torsten Reil, EF’s Matt Clifford, and Philipp Moehring, to name just a few.
“LabGenius is a full-stack protein engineering company: we combine artificial intelligence (AI), robotic automation and synthetic biology to evolve next-generation protein therapeutics,” founder and CEO Dr. James Field tells me.
“My central thesis, the thing that’s really the driving force behind the company, is the conviction that we’re entering an age in which humans will no longer be the sole agents of innovation. Instead, new knowledge, technologies and sophisticated real-world products will be invented by smart robotic platforms called empirical computation engines. An empirical computation engine is an artificial system capable
This post was originally published on this site